Development asset linked to Silence Therapeutics in public FDA and regional records.
pharma · Non-transfusion-dependent Thalassemia · Advanced Solid Tumors · SLN
Silence Therapeutics
Silence Therapeutics plc
Silence Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
London, GB HQ
1999 Founded
91 Employees
Public company Type
SLN · NYSE Ticker
Company details
- Status
- Public
- HQ
- London, GB
- Founded
- 1999
- Employees
- 91
- Programs
- 8
- Drugs
- 6
- Patents
- 3
Silence Therapeutics pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Silence Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Silence Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
Development asset linked to Silence Therapeutics in public FDA and regional records.
-
US regulatory status: approved.